1/8/2025  8:13:07 AM Chg. -1.050 Volume Bid8:13:07 AM Ask8:13:07 AM Market Capitalization Dividend Y. P/E Ratio
144.600EUR -0.72% 662
Turnover: 95,753.450
144.250Bid Size: 100 144.700Ask Size: 500 18.74 bill.EUR 1.52% 22.34

Business description

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 52,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
 

Management board & Supervisory board

CEO
Belén Garijo
Management board
Helene von Roeder, Dr. Kai Beckmann, Matthias Heinzel, Peter Guenter
Supervisory board
Michael Kleinemeier, Sascha Held, Anne Lange, Dietmar Oeter, Simon Thelen, Birgit Biermann, Katja Garcia Vila, Carla Kriwet, Barbara Lambert, Stefan Palzer, Alexander Putz, Christian Raabe, Michael Reinhart, Susanne Schaffert, Sandra Schwebke, Daniel Thelen
 

Company data

Name: Merck KGaA
Address: Frankfurter Str. 250,D-64293 Darmstadt
Phone: +49-6151-72-0
Fax: +49-6151-72-2000
E-mail: service@merckgroup.com
Internet: www.merck.de
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 66.28%
IPO date: 10/20/1995

Investor relations

Name: Constantin Fest
IR phone: +49-6151-72-3321
IR Fax: +49-6151-72-91-3321
IR e-mail: investor.relations@m...oup.com investor.relations@merckgroup.com

Company calendar

CW 10 | 3/6/2025 Annual Report
CW 17 | 4/25/2025 General Shareholder Meeting
CW 20 | 5/15/2025 Interim Report 1st Quarter/3 Months
CW 32 | 8/7/2025 Interim Report 2nd Quarter/6 Months
CW 46 | 11/13/2025 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Others
 
73.64%
BlackRock, Inc.
 
7.43%
Massachusetts Financial Services Company
 
5.06%
Sun Life Financial Inc.
 
4.91%
FMR LLC
 
3.02%
Amundi S.A.
 
2.99%
DWS Investment GmbH
 
2.95%